Otherwise, when patients showed a higher percentage of blasts (>10%), as described, this clinical feature also plays a role in the prognosis of MDS [21], together with mutational status of STAG2, SRSF2 and/or RUNX1 in the specific context of isolated +8 (Figure S2c). The gene discussed is SRSF2; the disease is myelodysplastic syndrome.